Lotronex Withdrawal Reflects Danger Of First-To-Market Products, GSK Says
Executive Summary
The withdrawal of Lotronex indicates the risk of launching the first product for a new indication in the current regulatory environment, GlaxoSmithKline Senior VP-New Product Development James Palmer maintained during a securities analysts meeting in London Feb. 22.
You may also be interested in...
FDA Cancer Chief Pazdur Backed By MD Anderson, Not PhRMA, For Commissioner
FDA Oncology Drug Products Division Director Richard Pazdur, MD, is among the candidates who have been asked to interview for the FDA commissioner position.
FDA Cancer Chief Pazdur Backed By MD Anderson, Not PhRMA, For Commissioner
FDA Oncology Drug Products Division Director Richard Pazdur, MD, is among the candidates who have been asked to interview for the FDA commissioner position.
Pfizer, PhRMA See Signs Of Drug Approval "Slowdown" At FDA
Pfizer believes that several of its pending products have been delayed by an "across-the-board" slowdown in FDA approvals, CEO Henry McKinnell told investors during the company's Jan. 24 quarterly conference call.